Hormonal contraceptive product

Abstract

The present invention relates to a hormonal contraceptive product having two hormonal components, an estrogen and a gestagen, and a method for the continuous suppression of the menstrual cycle by uninterrupted administration of the product of the invention.

What is claimed is:  
     
         1 . A method for hormonal contraception, comprising administering orally, transdermally or via depot to a mammal in need thereof, for a continuous and uninterrupted administration period, a contraceptive product comprising levonorgestrel and ethinyl estradiol, wherein said levonorgestrel and ethinyl estradiol are present in said contraceptive product at unchanged dosages throughout the administration period.  
     
     
         2 . The method of  claim 1 , wherein said ethinyl estradiol is present at a dosage of 120 μg per day.  
     
     
         3 . The method of  claim 2 , wherein the administration is oral.  
     
     
         4 . The method of  claim 3 , wherein the administration period is 9 months.  
     
     
         5 . The method of  claim 3 , wherein the administration period is 12 months.  
     
     
         6 . A method for continuous suppression of the menstrual cycle in a woman, comprising administering orally, transdermally or via depot to the woman in need thereof, for a continuous and uninterrupted administration period, a contraceptive product comprising levonorgestrel and ethinyl estradiol, wherein said levonorgestrel and ethinyl estradiol are present in said contraceptive product at unchanged dosages throughout the administration period.  
     
     
         7 . The method of  claim 6 , wherein said ethinyl estradiol is present at a dosage of 120 μg per day.  
     
     
         8 . The method of  claim 7 , wherein the administration is oral.  
     
     
         9 . The method of  claim 8 , wherein the administration period is 9 months.  
     
     
         10 . The method of  claim 8 , wherein the administration period is 12 months.  
     
     
         11 . A method for treating or inhibiting premenstrual syndrome, which comprises administering orally, transdermally, or via depot, to a mammal in need thereof, for a continuous and uninterupted administration period, an effective amount of a gestagen and an estrogen, wherein said gestagen and estrogen are present in unchanged dosages throughout the administration period.  
     
     
         12 . The method of  claim 11 , wherein said gestagen is selected from the group consisting of progesterone, chlormadinone acetate, northisterone acetate, cyprotherone acetate, desogestrel, and levonorgestrel; and 
 said estrogen is selected from the group consisting of ethinyl estradiol, mestranol, estradiol, estriol, estrone, and estrane.    
     
     
         13 . The method of  claim 12 , wherein said estrogen is ethinyl estradiol, which is present at a dosage of 1-20 μg per day.  
     
     
         14 . The method of  claim 13 , wherein said gestagen is levonorgesterel.  
     
     
         15 . The method of  claim 14 , wherein the administration is oral.